Taysha Gene Therapies holds routine annual meeting, elects directors and ratifies auditor

Filed June 2, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• medium

  Shareholders approved executive compensation with 82% support, though 18% voted against, suggesting some concern about pay levels or structure at the gene therapy company.

  Item 5.07: Say-on-pay vote verify on EDGAR →
• low

  Sean P. Nolan and Laura Sepp-Lorenzino elected to board for three-year terms through 2029. Sepp-Lorenzino received 27% withheld votes, higher than typical but not unusual for biotech boards.

  Item 5.07: Director elections verify on EDGAR →
• low

  Deloitte & Touche ratified as auditor for 2026 with 99.98% approval, indicating no shareholder concerns about financial reporting quality.

  Item 5.07: Auditor ratification verify on EDGAR →